CLRB - Cellectar Biosciences, Inc.

QQQ $ 453.98 $ 1.45 (0.32 %)

DIA $ 409.25 $ 1.92 (0.47 %)

SPY $ 546.15 $ 1.48 (0.27 %)

TLT $ 99.95 $ 0.57 (0.57 %)

GLD $ 231.04 $ -0.22 (-0.1 %)

Previous Close

$ 2.08

Open

$ 2.10

Bid

$ 2.11 x 100

Ask

$ 2.12 x 100

Day's Range

$ 2.10 - $ 2.15

52 Week Range

$ 1.82 - $ 4.45

Volume

286,233

Average Volume

Market Cap

74.57M

Beta (5Y Monthly)

$ 1.59

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	03-27-2024	12-31-2023	10-K
3	11-13-2023	09-30-2023	10-Q
4	08-14-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-09-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-05-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-21-2022	12-31-2021	10-K
11	11-08-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	03-02-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-09-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-12-2019	06-30-2019	10-Q
21	05-06-2019	03-31-2019	10-Q
22	02-26-2019	12-31-2018	10-K
23	11-13-2018	09-30-2018	10-Q
24	08-10-2018	06-30-2018	10-Q
25	05-11-2018	03-31-2018	10-Q
26	03-21-2018	12-31-2017	10-K
27	11-09-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-11-2017	03-31-2017	10-Q
30	03-15-2017	12-31-2016	10-K
31	11-10-2016	09-30-2016	10-Q
32	08-11-2016	06-30-2016	10-Q
33	05-12-2016	03-31-2016	10-Q
34	03-11-2016	12-31-2015	10-K
35	11-12-2015	09-30-2015	10-Q
36	08-12-2015	06-30-2015	10-Q
37	05-20-2015	03-31-2015	10-Q
38	03-24-2015	12-31-2014	10-K
39	11-12-2014	09-30-2014	10-Q
40	08-04-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Reported Friday, Cellectar Biosciences Ann...
08/26/2024 07:38:39

The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in...

Cellectar Biosciences Says Its Cash Balanc...
08/13/2024 10:42:11

gold-moves-higher-coca-cola-increases-fy24-forecast

Gold Moves Higher; Coca-Cola Increases FY2...
07/23/2024 18:32:19

why-comcast-shares-are-trading-lower-by-6-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Comcast Shares Are Trading Lower By 6%...
07/23/2024 17:21:51

Crude Oil Down 2%; GE Aerospace Earnings T...
07/23/2024 16:03:18

cancer-focused-cellectar-biosciences-stock-trades-lower-despite-meeting-goal-in-blood-cancer-study

Cancer-Focused Cellectar Biosciences Stock...
07/23/2024 14:49:57

Cellectar Biosciences stock drops 19.2% following the release of CLOVER WaM study results. The pivotal study for iopofosine I 1...

Cellectar Biosciences' Iopofosine I 131 Ex...
07/23/2024 10:51:50

56.4% major response rate exceeded 20% primary endpoint · 98.2% disease control rate achieved in heavily pretreated pati...

Cellectar Biosciences Generates $19.4M, Po...
07/22/2024 10:52:05

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, developmen...

Cellectar Biosciences Partners With City O...
05/29/2024 10:42:29

Cellectar Biosciences Files $300M Mixed Se...
05/24/2024 20:49:10

Cellectar Biosciences' Cash and Cash Equiv...
05/14/2024 10:48:39

Cellectar Biosciences Q1 2024 GAAP EPS $(0...
05/14/2024 10:34:59

Roth MKM Maintains Buy on Cellectar Biosci...
03/28/2024 17:03:11

Roth MKM analyst Jonathan Aschoff maintains Cellectar Biosciences (NASDAQ:CLRB) with a Buy and raises the price target from ...

Oppenheimer Reiterates Outperform on Celle...
03/28/2024 11:33:33

Oppenheimer analyst Jeff Jones reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Outperform and raises the price target ...

Cellectar Biosciences Says Cash and Cash ...
03/27/2024 10:52:03

Cellectar Biosciences Q4 EPS $(0.40) Beats...
03/27/2024 10:51:27

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of...

Earnings Scheduled For March 27, 2024
03/27/2024 09:02:44

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...

Earnings Preview For Cellectar Biosciences
03/26/2024 17:00:44

cellectar-biosciences-is-an-attractive-acquisition-target-according-to-this-analyst---heres-why

Cellectar Biosciences Is An 'Attractive Ac...
03/04/2024 18:48:03

Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, ach...

Roth MKM Reiterates Buy on Cellectar Biosc...
03/04/2024 16:44:46

Roth MKM analyst Jonathan Aschoff reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Buy and maintains $20 price target.